Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | KROS Keros Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $11.19 -1.5% | $15.06 -2.0% |
| StockIQ Score | 67B- Moderate Risk: High | 36F Weak Risk: Medium |
| Technical | 72B | 13F |
| Fundamental | 74B | 35F |
| Growth | 74B | 50C- |
| Fair Value | 67B- | 38F |
| News | 56C | 50C- |
| Quality | 58C | 50C- |
| Risk | 40D | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Keros Therapeutics (KROS) outperforms Ascentage Pharma (AAPG) in nearly every category. Its investor score (68 vs. 38) and overall rating (MODERATE vs. WEAK) are significantly stronger. KROS also leads in technical (79 vs. 19), fundamental (74 vs. 35), and valuation (67 vs. 38) scores, though growth scores are tied at 74. AAPG only excels in growth, which matches KROS’s score.